Gevers Begins a New Era of Managing Client IP as they Go Live on Anaqua’s AQX Law Firm 17-06-2025, 13:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

onsemi Announces $6 Billion Share Repurchase Authorization 19-11-2025, 04:15